Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
NCT01818661Phase 4Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jul 2018
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of flortaucipir in Apraxia of Speech (AOS), sponsored by Mayo Clinic. Started Jul 2018; status: recruiting.
02
Drugs
flortaucipir
03
Conditions
Apraxia of Speech (AOS)
Beyond the preview
Go deeper on NCT01818661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01818661.